Association between lorlatinib blood concentration and adverse events and clinical impact of dose modification.

Yukiko Shimoda IgawaTatsuya YoshidaReiko MakiharaMasahiro TorasawaAkiko TateishiYuji MatsumotoYuki ShinnoYusuke OkumaYasushi GotoHidehito HorinouchiNoboru YamamotoYuichiro Ohe

Published in: Lung cancer (Amsterdam, Netherlands) (2024)

Dose modification of lorlatinib was associated with successful management of AEs and decreased serum concentration of lorlatinib.

Keyphrases